Vertex Pharmaceuticals

Today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for our fifth cystic fibrosis (CF) medicine. This is an important step towards our goal of treating all people living with CF.

Today the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label expansion of our fourth cystic fibrosis (CF) medicine to include an expanded population with certain mutations. This marks an important step…

#Breaking: Today Health Canada granted marketing authorization for our fifth cystic fibrosis (CF) medicine.

We are proud to announce that our acute pain medicine has been recognized as a 2025 Breakthroughs Innovation Celebration winner by @PremierHA, a leading healthcare improvement company. Learn more: news.vrtx.com/news-releases/…

Today the European Commission approved our fifth cystic fibrosis (CF) medicine. This marks an important step towards our goal of treating all people with CF.

We are excited to share that data for our investigational stem cell-derived, fully differentiated islet cell therapy for #Type1Diabetes were published in @NEJM. Learn more: nejm.org

#Breaking: Today we announced updated data for our investigational islet cell therapy for the treatment of #Type1Diabetes. Learn more: news.vrtx.com/news-releases/…

Extended reimbursement agreement with the health authorities of #Slovenia: eligible children living with #CysticFibrosis ages 1 year and older will now have broad access to some of our medicines.

Today the European Commission approved the label expansion of our fourth cystic fibrosis (CF) medicine to include an expanded population with certain mutations. This marks an important step towards our goal of treating all people with CF.

#Breaking: The U.S. FDA approves our treatment for moderate-to-severe acute pain in adults. This is the first new class of pain medicine to be approved in over 20 years. Learn more: news.vrtx.com/news-releases/…

Extended reimbursement agreement with the National Health Insurance Fund in #Bulgaria: Since January 1 eligible children living with #CysticFibrosis ages 1 year and older will have broad access to some of our medicines.

Extended reimbursement agreement with the National Health Insurance in #Romania: Since the beginning of December eligible children living with #CysticFibrosis ages 2 years and older will have broad access to one of our medicines.

#Breaking: The U.S. FDA has approved our newest treatment for cystic fibrosis. Learn more: news.vrtx.com/press-releases

#Breaking: The U.S. FDA approves a label extension for #CysticFibrosis. We are excited to make this treatment available to more eligible patients. Learn more: vrtx.com

At the @ASH_hematology Annual Meeting this weekend, we are pleased to share new data on our gene-edited therapy. Learn more: vrtx.com/?utm_source=tw…

We are excited to share new data from multiple investigational kidney disease programs at the 2024 @ASNKidney Week Congress. Learn more: investors.vrtx.com/news-releases/… #KidneyWk

Today we announced that we will present pivotal Phase 3 data about our investigational pain program at the @ASALifeline annual meeting in Philly. Learn more: news.vrtx.com/news-releases/…

First reimbursement agreement in #Lithuania: Since October 1st, 2024, eligible people living with #CysticFibrosis have had reimbursed access to one of our #CysticFibrosis therapies. All EU Member States now have agreements in place for patients to access medicines that treat the…

Today the Mexican Federal Regulatory Authority (COFEPRIS) approved one of our latest cystic fibrosis (CF) medicines in Mexico. This marks an important step toward our goal of treating all people with CF.

#Breaking Health Canada grants marketing authorization of our treatment for #SickleCellDisease and #BetaThalassemia.